Impact of non-remission of depression on costs and resource utilization: From the COmorbidities and symptoms of DEpression (CODE) study

Current Medical Research and Opinion

Volumn 31, Issue 6, 2015, Pages 1165-1177

  Dennehy, Ellen B ^a,b   Robinson, Rebecca L ^a   Stephenson, Judith J ^c   Faries, Douglas ^a   Grabner, Michael ^c   Palli, Swetha Rao ^c   Stauffer, Virginia L ^a   Marangell, Lauren B ^a,d  

^a ELI LILLY AND COMPANY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c HEALTHCORE INC   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Comorbidity; Costs; Major depression; Remission

Indexed keywords

ALCOHOL; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; ALCOHOL CONSUMPTION; AMBULATORY CARE; ANEMIA; BODY MASS; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; DRUG COST; DRUG EXPOSURE; DRUG USE; EDUCATIONAL STATUS; FATIGUE; FEMALE; GENERALIZED ANXIETY DISORDER; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MEDICATION COMPLIANCE; MENTAL HEALTH; MENTAL HEALTH SERVICE; OBESITY; OUTPATIENT CARE; PAIN; PATIENT COMPLIANCE; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; PROPENSITY SCORE; PSYCHOGENIC PAIN; REMISSION; RETROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; SLEEP QUALITY; SMOKING; SYMPTOMATOLOGY; ADOLESCENT; ANXIETY; ECONOMICS; EPIDEMIOLOGY; FACTUAL DATABASE; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; MALE; MIDDLE AGED; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY; DATABASES, FACTUAL; DELIVERY OF HEALTH CARE; DEPRESSION; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84930368175     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1029893     Document Type: Review

References (42)

1. Soni, A. Trends in Use and Expenditures for Depression among U.S. Adults Age 18 and Older, Civilian Noninstitutionalized Population, 1999 and 2009. Statistical Brief #377. Rockville, MD: Agency for Healthcare Research and Quality, July 2012. Available at: http://www.meps.ahrq.gov/mepsweb/data- files/publications/st377/stat377.pdf [Last accessed 3 February 2015]
2. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465-75
3. Trivedi M, Rush A, Wisniewski S, et al.; for the STAR∗D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice. Am J Psychiatry 2006;163:28-40
4. Mauskopf JA, Simon GE, Kalsekar A, et al. Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder. Depress Anxiety 2009;26:83-97
5. Kim J-M, Kim S-W, Stewart R, et al. Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: the CRESCEND study. Hum Psychopharmacol Clin Exp 2011;26:41-50
6. Corey-Lisle PK, Nash R, Stang P, Swindle R. Response, partial response, and nonresponse in primary care treatment of depression. Arch Intern Med 2004;164:1197-204
7. Trivedi MH, Morris DW, Wisniewski SR, et al. Increase in work productivity of depressed individuals with improvement in depressive symptom severity. Am J Psychiatry 2013;170:633-41
8. Byford S, Barrett B, Despiegel N, Wade A. Impact of treatment success on health service use and cost in depression. Pharmacoeconomics 2011;29:157-70
9. Simon GE, Revicki D, Heiligenstein J, et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 2000;22:153-62
10. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS) clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54:573-83
11. Rush, AJ, Bernstein AH, Trivedi MH, et al. An evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiat 2006;59:493-501
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV, 4th edn. Washington (DC): American Psychiatric Association, 1994
13. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
14. Goldberg DB. Manual of the General Health Questionnaire. Windsor, England: NFER Publishing, 1978
15. Matza LS, Phillips GA, Revicki DA, et al. Development and validation of a patient-report measure of fatigue associated with depression. J Affect Disord 2011;134:294-303
16. Matza LS, Wyrwich KW, Phillips GA, et al. The Fatigue Associated with Depression Questionnaire (FAsD): responsiveness and responder definition. Qual Life Res 2013;22:351-60
17. Spitzer RL, Kroenke K, Williams JBW, Lowe B. A brief measure for assessing generalized anxiety disorder. Arch Intern Med 2006;166:1092-7
18. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. The diagnostic validity of the Athens Insomnia Scale. J Psychosomatic Res 2003;55:263-7
19. Atkinson TM, Mendoza TR, Sit L, et al. The Brief Pain Inventory and its 'pain at its worst in the last 24 hours' item: clinical trial endpoint considerations. Pain Med 2010;11:337-46
20. Dawson D, Pulay AJ, Grant BF. A comparison of two single-item screeners for hazardous drinking and alcohol use disorder. Alcohol Clin Exp Res 2010;34:364-74
21. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
22. Karve S, Cleves MA, Helm M, et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009;25:2303-10
23. Chernick MR. Bootstrap Methods: A Guide for Practitioners and Researchers. Hoboken, New Jersey: John Wiley & Sons Inc., 1999
24. Faries D, Leon AC, Haro JM, Obenchain RL. Analysis of Observational Health Care Data Using SAS. Cary, NC: SAS Institute Inc., 2010
25. Sobocki P, Ekman M, Agren H, et al. The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression. Int J Clin Pract 2006;60:791-8
26. Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry 2004;65:341-7
27. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiat 2002;63:963-71
28. Dennehy EB, Marangell LB, Martinez J, et al. Clinical and functional outcomes of patients who experience partial response to citalopram: secondary analysis of STAR∗D. J Psychiatr Pract 2014;20:178-87
29. Carter GC, Cantrell RA, Zarotsky V, et al. Comprehensive review of factors implicated in the heterogeneity of response in depression. Depress Anxiety 2012;29:340-54
30. Pan YJ, Knapp M, McCrone P. Impact of initial treatment outcome on long-term costs of depression: a 3-year nationwide follow-up study in Taiwan. Psychol Med 2014;44:1147-58
31. Arnow BA, Blasey CM, Lee J, et al. Relationships among depression, chronic pain, chronic disabling pain, and medical costs. Psychiatr Serv 2009;60:344-50
32. Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsych-otic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 2013;10:e1001403
33. Komossa K, Depping AM, Gaudchau A, et al. Second-generation antipsych-otics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 2010;12:CD008121
34. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd Edn. 2010. Available at: http://psychiatryonline.org/pb/assets/raw/sitewide/practice-guidelines/guidelines/mdd.pdf [Last accessed 20 April 2015]
35. Lam RW, Kennedy SH, Grigoriadis S, et al.; Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009;117(Suppl 1):S26-43
36. National Institute for Health and Clinical Excellence (NICE). Treatment and Management of Depression in Adults, Including Adults with a Chronic Physical Health Problem. London: NICE, October 2009. Available at: http://www.nice.org.uk/CG91 [Last accessed 20 April 2015]
37. Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med 2000;343:1942-50
38. Boudreau DM, Capoccia KL, Sullivan SD, et al. Collaborative care model to improve outcomes in major depression. Ann Pharmacother 2002;36:585-91
39. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to anti-depressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998;55:1128-32
40. Grenard JL, Munjas BA, Adams JL, et al. Depression and medication adherence in the treatment of chronic diseases in the United States: a meta-ana-lysis. J Gen Intern Med 2011;26:1175-82
41. Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Mental Health Findings, NSDUH Series H-47, HHS Publication No. (SMA) 13-4805. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013. Available at: Archive.samhsa.gov/data/NSDUH/2k12MH-FindingsandDetTables/2K12MHF/NSDUHmhfr2012.htm [Last accessed 4 February 2015]
42. Xing S, Di Paula BA, Lee HY, Cooke CE. Failure to fill electronically prescribed antidepressant medications: a retrospective study. Prim Care Companion CNS Disord 2011;13:PCC.10m00998